Fresenius Medical Care AG
FMS
Positions held
Your positionsFMS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Fresenius Medical Care AG operates in a stable industry with a growing demand for medical care facilities, driven by an aging population and increasing prevalence of chronic diseases.
- In the most recent quarter, revenue increased by 5% compared to the prior quarter, reaching $4.9 billion.
- The gross margin improved to 27% from 25.6% in the previous quarter.
- The company's current market sentiment is negative, with a 'Strong Sell' signal indicating potential challenges ahead.
- Fresenius Medical Care's trailing P/E ratio is 11.56, which is relatively low compared to industry averages, suggesting undervaluation but also potential concerns about future growth.
- The operating margin has been inconsistent, with a decline from 10.83% in Q4 2025 to 8.14% in Q1 2026.
Fundamentals
| Market cap | $11.11B | Enterprise value | $22.00B | Trailing P/E | 10.76 | Forward P/E | 6.99 |
| PEG | 0.67 | Price / book | 0.77 | Beta | 0.81 | Dividend yield | 4.17% |
| Revenue growth | 1.4% | Earnings growth | 5.5% | Gross margin | 26.4% | Operating margin | 10.8% |
| Profit margin | 4.8% | ROE | 8.5% | ROA | 4.0% | Debt / equity | 0.81 |
| Current ratio | 1.07 | Free cash flow | $2.02B | Analyst recommendation | hold | Mean target | $24.03 |
| 52w high | $27.54 | 52w low | $20.02 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $4.9B | $4.6B | $5.1B | $4.9B | $4.8B | — |
| Op margin | 11.1% | 8.1% | 10.8% | 10.3% | 7.9% | — |
| Net income | $218M | $118M | $327M | $275M | $225M | — |
| Gross margin | 27.0% | 25.6% | 27.4% | 25.4% | 25.3% | — |
| Gross profit | $1.3B | $1.2B | $1.4B | $1.2B | $1.2B | — |
| Operating income | $537M | $376M | $549M | $502M | $380M | — |
- Revenue +5% vs prior quarter ($4.9B vs $4.6B).
- Gross margin 27% (was 25.6% prior quarter).
- Operating margin expanded to 11%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $19.6B | $19.3B | $19.5B | $19.4B |
| Op margin | 9.3% | 7.6% | 7.6% | 7.5% |
| Net income | $978M | $538M | $499M | $673M |
| Gross margin | 25.6% | 24.6% | 25.3% | 25.2% |
| Gross profit | $5.0B | $4.8B | $4.9B | $4.9B |
| Operating income | $1.8B | $1.5B | $1.5B | $1.5B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
2026-10-07 · Fresenius Medical Care Names Shervin Korangy as CEO, Board Chair
2026-09-29 · European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
2026-09-29 · Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
2026-09-29 · Berenberg Downgrades Fresenius Medical Care to Hold From Buy, Cuts Price Target to $24 From $34.50
2026-09-25 · Fresenius Medical Care Plans to Exit China Peritoneal Dialysis Business
2026-09-25 · Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
2026-09-07 · FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk
2026-09-03 · Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
2026-09-03 · Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Price (daily)
Full chart · RSI · MACD · patterns